NANOVIRICIDES, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate
NANOVIRICIDES, INC. (NNVC) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate of 55.12% for the 3-month period ending 2018-09-30, per its 10-Q filed 2018-11-14.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate · last filed 2018-11-14
- NANOVIRICIDES, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2018-09-30 was 55.12%.
- NANOVIRICIDES, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2015-09-30 was 58.39%.
- NANOVIRICIDES, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2014-12-31 was 45.19%.
- NANOVIRICIDES, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2014-03-31 was 78.44%.
- NANOVIRICIDES, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2018 was 58.33%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 0 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 1 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 12 month |
|---|---|---|---|---|---|
| 2018-09-30 | 55.12% 10-Q · filed 2018-11-14 | ||||
| 2018-06-30 | 58.33% 10-K · filed 2018-10-12 | ||||
| 2015-12-31 | 57.81% 10-Q · filed 2016-02-09 | ||||
| 2015-09-30 | 58.39% 10-Q · filed 2015-11-09 | ||||
| 2014-12-31 | 45.19% 10-Q · filed 2015-02-25 | ||||
| 2014-08-15 | 91.68% 10-Q/A · filed 2015-02-23 | ||||
| 2014-03-31 | 78.44% 10-Q · filed 2014-05-15 | ||||
| 2014-01-31 | 78.39% 10-K · filed 2014-09-30 | ||||
| 2013-09-30 | 78.39% 10-K · filed 2014-09-30 | 78.39% 10-Q · filed 2014-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 | |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |